ArticleEuropean journal of case reports in internal medicine2026
Semaglutide-Induced Ischemic Colitis in A Middle-Aged Female Without Vascular Risk Factors.
Article in European journal of case reports in internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic colitis (IC) typically occurs in patients with vascular risk factors. We report a case of a 53-year-old woman without comorbidities who developed IC after initiating semaglutide. She presented with acute abdominal pain and haematochezia. Imaging, colonoscopy, and biopsy confirmed IC, while infectious workup was negative. Symptoms resolved following discontinuation of semaglutide and supportive care. This case highlights a potential association between glucagon-like peptide-1 receptor agonists and IC and underscores the importance of recognizing rare adverse effects in patients without traditional risk factors. LEARNING POINTS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may be associated with ischemic colitis even in patients without traditional vascular risk factors, highlighting the need for heightened clinical suspicion in atypical presentations.New-onset abdominal pain and haematochezia in patients receiving GLP-1RAs should prompt early evaluation for ischemic colitis, including imaging and endoscopic assessment to exclude alternative diagnoses.Prompt discontinuation of the suspected offending agent and supportive management can lead to complete clinical recovery, emphasizing the importance of early recognition and intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.